卵巢恶性肿瘤保留生育功能治疗

doi:10.3760/cma.j.issn.1673-422X.2016.06.021

摘要/Abstract

摘要： 卵巢癌保留生育功能的治疗是针对有生育需求并符合条件的卵巢癌患者提出的一种新型治疗理念。目前国际上对其适应证及安全性仍存在争议。其手术方式是在传统手术的基础上保留子宫和至少一侧的卵巢，术后再选择合理有效的放化疗方案进行辅助治疗，同时行卵巢保护，且根据个体差异选择合适的妊娠时机，最终达到理想的肿瘤预后及妊娠结局的目的。

关键词: 卵巢肿瘤, 生育力, 治疗, 妊娠

Abstract: As a new type of treatment for ovarian cancer, the fertility sparing surgery is put forward for patients who has fertility requirements and the surgical indication. But the indications and safety are still controversial at present on the international. The operation is based on the traditional surgery way, the retention of the uterus and at least one side of the ovary, and then the corresponding adjuvant chemotherapy and ovarian protection, and choosing the right pregnancy timing based on individual difference, to the excellent oncologic outcomes and the favorable reproductive outcomes.

Key words: Ovarian neoplasms, Fertility, Therapy, Pregnancy

魏蒙，杨永秀. 卵巢恶性肿瘤保留生育功能治疗[J]. 国际肿瘤学杂志, 2016, 43(6): 475-478.

Wei Meng, Yang Yongxiu. Fertility preserving treatment of ovarian malignant tumor[J]. Journal of International Oncology, 2016, 43(6): 475-478.

参考文献

［1］ Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory［J］. Am J Surg Pathol, 2010, 34(3): 433-443. DOI: 10.1097/PAS.0b013e3181cf3d79. ［2］ Ditto A, Martinelli F, Bogani G, et al. Longterm safety of fertility sparing surgery in early stage ovarian cancer: comparison to standard radical surgical procedures［J］. Gynecol Oncol, 2015, 138(1): 78-82. DOI: 10.1016/j.ygyno.2015.05.004. ［3］ Kajiyama H. Fertility sparing surgery in patients with early stage epithelial ovarian cancer: implication of survival analysis and lymphadenectomy［J］. J Gynecol Oncol, 2014, 25(4): 270-271. DOI: 10.3802/jgo.2014.25.4.270. ［4］ Billmire DF, Rescorla FJ, Ross JH, et al. Impact of central surgical review in a study of malignant germ cell tumors［J］.J Pediatr Surg, 2015, 50(9): 1502-1505. DOI: 10.1016/j.jpedsurg.2014.12.008. ［5］ González Martín A, Redondo A, Jurado M, et al. GEICO (Spanish group for investigation on ovarian cancer) treatment guidelines in ovarian cancer 2012［J］. Clin Transl Oncol, 2013, 15(7): 509-525. DOI: 10.1007/s12094-012-0995-8. ［6］ Yang ZJ, Liu ZC, Wei RJ, et al. An analysis of prognostic factors in patients with ovarian malignant germ cell tumors who are treated with fertilitypreserving surgery［J］. Gynecol Obstet Invest, 2015, In press. DOI: 10.1159/000381771. ［7］ Park JY, Kim DY, Suh DS, et al. Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors［J］. Gynecol Oncol, 2015, 137(3): 418-422. DOI: 10.1016/j.ygyno.2015.03.054. ［8］ Chhabra S, Kutchi I. Fertility preservation in gynecological cancers［J］. Clin Med Insights Reprod Health, 2013, 7: 49-59. DOI: 10.4137/CMRH.S10794. ［9］ Jung KW, Won YJ, Kong HJ, et al. Prediction of cancer incidence and mortality in Korea, 2014［J］. Cancer Res Treat, 2014, 46(2): 124-130. DOI: 10.4143/crt.2014.46.2.124. ［10］ Kajiyama H, Shibata K, Mizuno M, et al. Fertilitysparing surgery in patients with clearcell carcinoma of the ovary: is it possible?［J］. Hum Reprod, 2011, 26(12): 32973302. DOI: 10.1093/humrep/der342. ［11］ Satoh T, Tsuda H, Kanato K, et al. A nonrandomized confirmatory study regarding selection of fertilitysparing surgery for patients with epithelial ovarian cancer: Japan Clinical Oncology Group Study (JCOG1203)［J］. Jpn J Clin Oncol, 2015, 45(6): 595-599. DOI: 10.1093/jjco/hyv032. ［12］ Kajiyama H, Mizuno M, Shibata K, et al. Recurrencepredicting prognostic factors for patients with earlystage epithelial ovarian cancer undergoing fertilitysparing surgery: a multiinstitutional study［J］. Eur J Obstet Gynecol Reprod Biol, 2014, 175(175): 97-102. DOI: 10.1016/j.ejogrb.2014.01.014. ［13］ Leblanc E, Narducci F, Farre I, et al. Radical fimbriectomy: a reasonable temporary riskreducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development［J］. Gynecol Oncol, 2011, 121(3): 472-476. DOI: 10.1016/j.ygyno.2011.02.012. ［14］ Bachmann C, Brucker SY, Kraemer B, et al. The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer［J］. J Cancer Res Clin Oncol, 2015, 141(8): 1475-1480. DOI: 10.1007/s00432-015-1945-y. ［15］ Chatchotikawong U, Ruengkhachorn I, Leelaphatanadit C, et al. 8year analysis of the prevalence of lymph nodes metastasis, oncologic and pregnancy outcomes in apparent earlystage malignant ovarian germ cell tumors［J］. Asian Pac J Cancer Prev, 2015, 16(4): 16091613. ［16］ Kottarathil VD, Antony MA, Nair IR, et al. Recent advances in granulosa cell tumor ovary: a review［J］. Indian J Surg Oncol, 2013, 4(1): 37-47. DOI: 10.1007/s13193-012-0201-z. ［17］ Papic JC, Finnell SM, Slaven JE, et al. Predictors of ovarian malignancy in children: overcoming clinical barriers of ovarian preservation［J］. J Pediatr Surg, 2014, 49(1): 144-147; discussion 147148. DOI: 10.1016/j.jpedsurg.2013.09.068. ［18］ Pereira A, PérezMedina T, Magrina JF, et al. International federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with nodepositive epithelial ovarian cancer［J］. Int J Gynecol Cancer, 2015, 25(1): 49-54. DOI: 10.1097/IGC.0000000000000316. ［19］ Vassilakopoulou M, Boostandoost E, Papaxoinis G, et al. Anticancer treatment and fertility: effect of therapeutic modalities on reproductive system and functions［J］. Crit Rev Oncol Hematol, 2016, 97： 338-334. DOI: 10.1016/j.critrevonc.2015.08.002. ［20］ Chen CA, Lin H, Weng CS, et al. Outcome of 3day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: a Taiwanese Gynecologic Oncology Group study［J］. Eur J Cancer, 2014, 50(18): 3161-3167. DOI: 10.1016/j.ejca.2014.10.006. ［21］ Solheim O, Trope CG, Rokkones E, et al. Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era"［J］. Gynecol Oncol, 2015, 136(2): 224-229. DOI: 10.1016/j.ygyno. 2014.12.010. ［22］ Park CY, Jung SY, Lee KB, et al. The feasibility and efficacy of gonadotropinreleasing hormone agonists for prevention of chemotherapy induced ovarian failure in patient with gynecological malignancies［J］. Obstet Gynecol Sci, 2014, 57(6): 478-483. DOI: 10.5468/ogs.2014.57.6.478. ［23］ Blumenfeld Z. Fertility preservation and GnRHa for chemotherapy: debate［J］. Cancer Manag Res, 2014, 6: 313-315. DOI: 10.2147/CMAR.S66600. ［24］ Gamzatova Z, Komlichenko E, Kostareva A, et al. Autotransplantation of cryopreserved ovarian tissueeffective method of fertility preservation in cancer patients［J］. Gynecol Endocrinol, 2014, 82(2): 141-145. DOI: 10.3109/09513590.2014.945789. ［25］ Fruscio R, Corso S, Ceppi L, et al. Conservative management of earlystage epithelial ovarian cancer: results of a large retrospective series［J］. Ann Oncol, 2013, 24(1): 138-144. DOI: 10.1093/annonc/mds241. ［26］ Karalk A, Tal T, reyen I, et al. Juvenile granulosa cell ovarian tumor: clinicopathological evaluation of ten patients［J］. J Turk Ger Gynecol Assoc, 2015, 16(1): 32-34. DOI: 10.5152/jtgga.2015.15207.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[4]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[5]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[6]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[7]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[8]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[9]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[10]	王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛. 铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 239-244.
[11]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[12]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[13]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[14]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[15]	岳红云, 张百红. 肿瘤的分化治疗[J]. 国际肿瘤学杂志, 2024, 51(2): 109-113.